DiWB‐1: A Luteinizing Hormone Releasing Hormone (LHRH)‐Targeted Peptide‐Drug Conjugate (PDC) With Enhanced Tumor Selectivity and PI3K Inhibition Efficacy
Authors:
- 22 June 2025
- journal article
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (6) , e70021
Abstract
Phosphoinositide 3‐kinase (PI3K) inhibitors have demonstrated efficacy in cancer therapy; yet, their clinical use is often restricted by off‐target toxicity. Peptide‐drug conjugates (PDCs) have emerged as a strategy to improve tumor selectivity by targeting receptors overexpressed in malignant cells. Luteinizing hormone‐releasing hormone receptors (LHRHR), upregulated in several cancers, present an attractive target for such approaches. In this study, we obtained an LHRHR‐targeting peptide IV‐6, characterized by high receptor affinity and robust metabolic stability. IV‐6 was then conjugated to the PI3K inhibitor buparlisib, forming the target PDC, DiWB‐1. In Vitro, DiWB‐1 exhibited superior antineoplastic effects against LHRHR‐positive MDA‐MB‐231 cells, with an IC50 of 1.8 μM, compared with 2.4 μM for buparlisib, and demonstrated reduced toxicity in normal cells. In Vivo, DiWB‐1 showed considerable tumor‐suppressive effects while minimizing systemic toxicity, avoiding the hepatic and renal damage, as well as hyperglycemia, observed with buparlisib treatment. Pharmacokinetic studies further indicated that DiWB‐1 had favorable metabolic stability, with a half‐life of 5.6 h, slightly exceeding that of triptorelin (4.2 h). These findings suggest that DiWB‐1 holds promise as a selective, potent, and long‐acting anticancer PDC, warranting further investigation.Keywords
This publication has 61 references indexed in Scilit:
- Cyclic Peptides for Drug DevelopmentAngewandte Chemie International Edition, 2023
- Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050JAMA Oncology, 2023
- Targeting self-enhanced ROS-responsive artesunatum prodrug nanoassembly potentiates gemcitabine activity by down-regulating CDA expression in cervical cancerChinese Chemical Letters, 2023
- Drug conjugate-based anticancer therapy - Current status and perspectivesCancer Letters, 2022
- Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?Acta Pharmaceutica Sinica B, 2022
- The role of cell‐penetrating peptides in potential anti‐cancer therapyClinical and Translational Medicine, 2022
- Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatmentCancer Medicine, 2022
- pH‐Responsive Polymer Nanoparticles for Drug DeliveryMacromolecular Rapid Communications, 2019
- Design, synthesis and biological evaluation of peptide dendrimers with wound healing promoting activityMedicinal Chemistry Research, 2017
- An 125I-labeled octavalent peptide fluorescent nanoprobe for tumor-homing imaging in vivoBiomaterials, 2012